Protocol for the management of acute severe ulcerative colitis in children

Similar documents
Algorithm for managing severe ulcerative colitis

Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients

Evaluation of treatment effect in UC and CD (children)

Guideline Ulcerative colitis: management

Achieving Success in Ulcerative Colitis: the Role of Infliximab

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

Management of the Hospitalized IBD Patient. Drew DuPont MD

Predicting outcome in severe ulcerative colitis

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Diarrhoea on the AMU. Dr Chris Roseveare

Nutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary

Infliximab (Remicade) for paediatric ulcerative colitis - second line

Treatment of Pediatric IBD: What is Different?

TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

What s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff

Efficacy and Safety of Treatment for Pediatric IBD

Implementation of disease and safety predictors during disease management in UC

Which is the Safest Strategy to Treat Moderate to Severe IBD?

Qualification opinion

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

Trust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)

Efficacy and Safety of Treatment for Pediatric IBD

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience

Diarrhoea for the Acute Physician

A Case of Inflammatory Bowel Disease

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Current management options and recent advances in IBD

Mucosal healing: does it really matter?

INFLAMMATORY BOWEL DISEASE

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

Clinical Study Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis

Health supervision and prevention of complications in the child with IBD. Athos Bousvaros MD MPH

CLINICAL GUIDELINES ID TAG

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

Paediatric Gastroenterology Clinical Network. Management of Inflammatory Bowel Disease in Children and Adolescents in New Zealand

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s

LRI Children s Hospital

Medical Therapy for Pediatric IBD: Efficacy and Safety

Corporate Medical Policy

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

The York Faecal Calprotectin Care Pathway for use in primary care. James Turvill

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

PEDIATRIC INFLAMMATORY BOWEL DISEASE

Indications for use of Infliximab

Irritable Bowel Syndrome vs Inflammatory Bowel Disease

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Αναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας

Positioning Biologics in Ulcerative Colitis

Diagnosing and Managing IBS in IBD Patients. September 2012

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

SWL Drug Pathway Ulcerative Colitis Version 3 (Oct 2018) (based on NICE ulcerative colitis commissioning algorithm - with local adaptation)

fever a persistent unexplained change in bowel habit in somebody over 50 years of age a family history of bowel or ovarian cancer.

Use of extrapolation in small clinical trials:

Objectives RECENT ADVANCES IN FECAL MICROBIOTA TRANSFORMATION. TRANSPLANT in Inflammatory Bowel Disease

Genetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease

Ulcerative Colitis: State of the Art 2006

Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews

Diagnostic techniques for surveillance of dysplasia

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Ali Keshavarzian MD Rush University Medical Center

Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Inflammatory Bowel Disease: Clinical updates. Dr Jeff Chao Princess Alexandra Hospital

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers

Dr Adele Melton Gastroenterologist MBChB (Otago), FRACP

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

Clinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases

Lifting the lid on a difficile problem part 2 (Clinical) Evidence Based Practice. Problem in evolution (1) Problem in evolution (1) Interventions (2)

Case Discussion. Nutrition in IBD. Rémy Meier MD. Ulcerative colitis. Crohn s disease

The Role of Surgery in Inflammatory Bowel Disease. Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health

Pediatric Gastroenterology Referral Guidelines

FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015

Exclusive Elemental Nutrition-Children s Perceptions Siobhain Kiernan RGN, RCN, RNP, Msc in Nursing

Guidelines on the Management of a Child with Sickle Cell Disease and low Haemoglobin

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

Guideline scope Diverticular disease: diagnosis and management

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Ambulatory Emergency Care Pathways. Painless Obstructive Jaundice

Children who are neutropenic and unwell, even if normothermic, should be assumed to have infection and be treated appropriately.

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Transcription:

Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five years from diagnosis a significantly higher percentage of patients with childhood onset UC are admitted to emergency units for acute severe colitis, compared to adult onset disease (1,3,4) More children fail intravenous steroids during an acute severe episode (,6) Consequently, this translates into higher colectomy rates in children compared to adult UC populations. It is therefore important to promptly diagnose, initiate treatment and monitor progress during an acute UC flare up. Purpose To deliver standardised/evidenced based practice for all patients admitted with severe Ulcerative Colitis in keeping with current guidelines and IBD standards. These guidelines are intended to assist management of acute severe UC in first 24-72 hours of presentation. Subsequent management needs to be individualised depending on the clinical improvement and not covered in this document 9. Criteria for Inclusion This protocol apply to those patients who meet the following criteria Patient that have confirmed diagnosis of UC Patient suspected to have a severe flare by Truelove & Witts (7) Classification Score. Six bloody stools associated with one or more further activity within the severe category. Activity Mild Moderate Severe No Bloody Stools per day <4 4-6 >6 Temp Afebrile Intermediate >37.8 Heart Rate Normal Intermediate >9 Haemoglobin (g/dl) >11 1.-11 <1. ESR (mm/h) <2 2-3 >3 Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21

Assessment In addition to usual clinical assessment of an acutely unwell child, it is important to look for following points History Frequency of stooling, stool consistency, blood in stools, nocturnal stools, weight loss, abdominal pain, limitation of activity to calculate Paediatric Ulcerative Colitis Activity Index (PUCAI) which is only specific for ulcerative colitis and not Crohn s disease 8. Check doses of current medications and patient compliance Examination Look for vital signs tachycardia, anaemia, jaundice, dehydration. Abdominal tenderness (Toxic megacolon) Investigations 1. Send stool mc/s (2 samples) and stool for Cl Diff, Faecal calprotectin 2. Blood tests (FBC, Biochemistry including LFTs, CRP, amylase, Alpha 1 acid glycoprotein/esr). Consider sending Azathioprine metabolites (6TGN/6MMPN) if poor compliance is suspected 3. Request abdominal x ray (AXR) to look for toxic megacolon. Repeat AXR should be dictated by the initial AXR and condition Toxic megacolon - Defined as >.cms diameter transverse colon or > 9cms caecum. If present on admission, an urgent surgical referral must be made and commenced on IV antibiotics (cefuroxime and metronidazole). 24-48 hours of intensive medical therapy may be considered provided patient is sufficiently stable, but a failure to respond by 48 hours, or development of further dilatation during medical therapy mandates consideration of colectomy. Management 1. Calculate PUCAI score (see table 1) and monitor daily to monitor progress. 2. Start methyl prednisolone 1-1. mg per kilogram (max 6 mg) in 2 divided doses. 3. Consider IV antibiotics (as above) if febrile/ infection suspected or likely to need colectomy. 4. Monitor daily PUCAI score. Consider IV fluids if clinically dehydrated. 6. Consider surgical review if AXR suggestive of toxic megacolon 7. Discuss with Paediatric Gastroenterology Consultant on service at Leicester Royal Infirmary (LRI) at earliest opportunity via switchboard. 8. Consider transfer to LRI if clinically indicated. Please note this protocol is only intended for patients with acute severe UC and not for those who have mild to moderate disease. Please discuss with senior colleagues for advice. Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21

Table 1: PAEDIATRIC ULCERATIVE COLITIS INDEX (PUCAI) Name/DOB: Date: (1) Abdominal pain No pain Pain can be ignored Pain cannot be ignored (2) Rectal bleeding None Small amount in <% stools Small amount with most stools Large amount (>% stool) (3) Stool consistency of most stools Formed Partially formed Completely unformed (4) Number of stools per 24h -2 3-6-8 >8 () Nocturnal stools (any episode causing wakening) No Yes (6) Activity level No limitation of activity Occasional limitation of activity Points 1 1 2 3 1 1 1 1 1 Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21

Severe restricted activity SUM OF PUCAI (-8) Figure 2: Treatment algorithm for acute severe UC (8) Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21

Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21

References: 1. Lev-Tzion R, Turner D. Is pediatric IBD treatment different than in adults? Minerva Gastroenterol Dietol 212;8:137. 2. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 28;13:1114 22. 3. Turner D, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 28;7:331 8. 4. Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, et al. The pattern and outcome of acute severe colitis J Crohns Colitis 21;4:431 7.. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 27;:13 1. 6. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 211;17:44 9. 7. Truelove S C, Witts L. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ. 19;2:141 148 8. D Turner et al, Am J Gastroenterol. 211 Apr;16(4):74-88. Epub 211 Jan 11 9. Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines. JPGN Volume, Number 3, September 212 Title: Protocol for the management of acute severe ulcerative colitis in children Last reviewed: July 21